Cargando…

Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders

Neuroinflammation represents a common trait in the pathology and progression of the major psychiatric and neurodegenerative disorders. Neuropsychiatric disorders have emerged as a global crisis, affecting 1 in 4 people, while neurological disorders are the second leading cause of death in the elderl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Yoo Jin, Tweedie, David, Scerba, Michael T., Kim, Dong Seok, Palmas, Maria Francesca, Pisanu, Augusta, Carta, Anna R., Greig, Nigel H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039148/ https://www.ncbi.nlm.nih.gov/pubmed/33854417 http://dx.doi.org/10.3389/fnins.2021.656921

Ejemplares similares

A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders
por: Kopp, Katherine O., et al.
Publicado: (2023)

IMiDs for myeloma induced renal impairment
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
por: Suzuki, Kazuhito, et al.
Publicado: (2023)

Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs)
por: Liu, W M, et al.
Publicado: (2009)

Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide
por: Bartlett, J B, et al.
Publicado: (2005)

Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them
por: Cippitelli, Marco, et al.
Publicado: (2021)

Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma
por: Lien, I-Chia, et al.
Publicado: (2014)

Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF
por: Corti, Angelo, et al.
Publicado: (2010)

Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide
por: Furihata, Hirotake, et al.
Publicado: (2020)

IMiDs induce FAM83F degradation via an interaction with CK1α to attenuate Wnt signalling
por: Dunbar, Karen, et al.
Publicado: (2020)

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma
por: Fionda, Cinzia, et al.
Publicado: (2015)

IMiDs Augment CD3-Bispecific Antibody–Induced CD8(+) T-Cell Cytotoxicity and Expansion by Enhancing IL2 Production
por: Li, Ji, et al.
Publicado: (2023)

An IMiD-induced SALL4 degron system for selective degradation of target proteins
por: Yamanaka, Satoshi, et al.
Publicado: (2020)

309 MYC Inhibition Overcomes IMiD Resistance in Heterogeneous Multiple Myeloma Populations
por: Davis, Lorraine, et al.
Publicado: (2022)

A New Strategy for the Old Challenge of Thalidomide: Systems Biology Prioritization of Potential Immunomodulatory Drug (IMiD)-Targeted Transcription Factors
por: Kowalski, Thayne Woycinck, et al.
Publicado: (2023)

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
por: Herviou, Laurie, et al.
Publicado: (2018)

Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?
por: Sponaas, Anne Marit, et al.
Publicado: (2021)

GWAS in IMIDs
por: Plenge, R M
Publicado: (2010)

IMID-Biobank: Biobank of immune-mediated inflammatory diseases (IMIDs)
por: Marsal, S, et al.
Publicado: (2010)

iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells
por: Bouguenina, Habib, et al.
Publicado: (2023)

In silico analysis of enantioselective binding of immunomodulatory imide drugs to cereblon
por: Murai, Takahiro, et al.
Publicado: (2016)

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner
por: Dimopoulos, Konstantinos, et al.
Publicado: (2017)

Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments
por: Jung, Yoo Jin, et al.
Publicado: (2019)

Role of IRF4 in resistance to immunomodulatory (IMid) compounds(®) in Waldenström’s macroglobulinemia
por: Bertrand, Elisabeth, et al.
Publicado: (2017)

Base‐Assisted Imidization: A Synthetic Method for the Introduction of Bulky Imide Substituents to Control Packing and Optical Properties of Naphthalene and Perylene Imides
por: Mahl, Magnus, et al.
Publicado: (2020)

The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma
por: Heider, Michael, et al.
Publicado: (2021)

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma
por: Gooding, Sarah, et al.
Publicado: (2022)

IMiDs uniquely synergize with TKIs to upregulate apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressing a dominant-negative IKZF1 isoform
por: Harama, Daisuke, et al.
Publicado: (2021)

Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson’s Disease
por: Palmas, Maria Francesca, et al.
Publicado: (2022)

Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis
por: Warsame, Rahma, et al.
Publicado: (2020)

The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors
por: Abruzzese, Maria Pia, et al.
Publicado: (2019)

VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo
por: Yu, Tengteng, et al.
Publicado: (2020)

Mechanochemical N-alkylation of imides
por: Briš, Anamarija, et al.
Publicado: (2017)

CO(2) Separation by Imide/Imine Organic Cages
por: La Cognata, Sonia, et al.
Publicado: (2022)

Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy
por: Thakurta, A, et al.
Publicado: (2014)

pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4(CRBN) ubiquitin ligase
por: An, Jian, et al.
Publicado: (2017)

Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma
por: Costacurta, Matteo, et al.
Publicado: (2020)

A comparison of peripheral blood stem cell collection outcomes for multiple myeloma; mobilization matters in the era of IMiD induction
por: Chandler, Thea, et al.
Publicado: (2023)

Synthesis and Properties of Poly(imides) and Poly(imides)/Ionic Liquid Composites Bearing a Benzimidazole Moiety
por: Terraza, Claudio A., et al.
Publicado: (2019)

Mechanisms of accelerated atherosclerosis associated with IMIDs
por: Mallat, Z
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ju66vb8kd7gv2ipdc4hf4nhdf6